D. E. Shaw & Co., Inc. Cytom X Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $1,080 - $2,098	-766 Reduced 6.62%	10,811 $23,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $1.55 $66,251 - $95,971	-61,917 Reduced 84.25%	11,577 $17,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $1.87 $71,777 - $106,526	-56,966 Reduced 43.67%	73,494 $94,000
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $240,237 - $327,131	-170,381 Reduced 56.63%	130,460 $224,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $469,948 - $914,495	-317,533 Reduced 51.35%	300,841 $454,000
Q4 2022 Feb 14, 2023	BUY	$1.19 - $1.91 $153,205 - $245,901	128,744 Added 26.29%	618,374 $989,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $297,848 - $477,041	242,153 Added 97.85%	489,630 $710,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $118,614 - $224,050	77,526 Added 45.62%	247,477 $453,000
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $453,769 - $795,370	169,951 New	169,951 $454,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $101,769 - $194,334	-26,297 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $704,795 - $1.05 Million	-163,147 Reduced 86.12%	26,297 $134,000
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $816,804 - $1.28 Million	-129,037 Reduced 40.52%	189,444 $1.2 Million
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $1.96 Million - $2.68 Million	-297,518 Reduced 48.3%	318,481 $2.46 Million
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $669,716 - $817,736	103,511 Added 20.2%	615,999 $4.04 Million
Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $965,411 - $1.3 Million	147,391 Added 40.37%	512,488 $3.41 Million
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $1.17 Million - $2.31 Million	-157,555 Reduced 30.15%	365,097 $3.04 Million
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $640,590 - $1.53 Million	-177,449 Reduced 25.35%	522,652 $4.01 Million
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $1.88 Million - $3.24 Million	363,097 Added 107.74%	700,101 $5.82 Million
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $35,497 - $58,922	4,810 Added 1.45%	337,004 $2.49 Million
Q2 2019 Aug 14, 2019	SELL	$9.35 - $11.41 $444,686 - $542,659	-47,560 Reduced 12.52%	332,194 $3.73 Million
Q1 2019 May 15, 2019	BUY	$9.5 - $19.16 $2.34 Million - $4.71 Million	246,072 Added 184.07%	379,754 $4.08 Million
Q4 2018 Feb 14, 2019	BUY	$12.69 - $18.61 $144,221 - $211,502	11,365 Added 9.29%	133,682 $2.02 Million
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $257,322 - $376,712	14,264 Added 13.2%	122,317 $2.26 Million
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $652,902 - $906,367	30,538 Added 39.4%	108,053 $2.47 Million
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $1.02 Million - $1.61 Million	47,034 Added 154.31%	77,515 $2.21 Million
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $341,962 - $415,573	17,998 Added 144.18%	30,481 $643,000
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $168,894 - $226,816	12,483	12,483 $227,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.7M

Call Options Held

112K

Put Options Held

8.3K

Tang Capital Management LLC San Diego, CA

7.81M
Shares

$8.28 Million
0.79% of portfolio
Bvf Inc San Francisco, CA

5.23M
Shares

$5.54 Million
0.2% of portfolio
Vanguard Group Inc Valley Forge, PA

5.16M
Shares

$5.47 Million
0.0% of portfolio
Janus Henderson Group PLC London, X0

4.81M
Shares

$5.1 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.1M
Shares

$3.29 Million
0.01% of portfolio

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account